MARKET

CDXC

CDXC

ChromaDex
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.16
-0.37
-4.91%
After Hours: 7.12 -0.04 -0.56% 19:07 05/10 EDT
OPEN
7.66
PREV CLOSE
7.53
HIGH
7.72
LOW
7.13
VOLUME
821.48K
TURNOVER
--
52 WEEK HIGH
23.66
52 WEEK LOW
3.820
MARKET CAP
486.40M
P/E (TTM)
-21.9296
1D
5D
1M
3M
1Y
5Y
10 Biggest Price Target Changes For Monday
BMO Capital boosted The Middleby Corporation (NASDAQ: MIDD) price target from $225 to $250. Middleby shares rose 1.9% to close at $182.83 on Friday.
Benzinga · 13h ago
HC Wainwright & Co. Maintains Buy on ChromaDex, Lowers Price Target to $11
HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and lowers the price target from $16 to $11.
Benzinga · 14h ago
--HC Wainwright Adjusts ChromaDex PT to $11 From $16, Maintains Buy Rating
MT Newswires · 16h ago
Global Worldwide Zeaxanthine Market Outlook, Industry Analysis and Prospect 2021-2026
Heraldkeepers · 1d ago
DJ ChromaDex CEO Robert Fried on Q1 2021 Results -- Earnings Call Transcript >CDXC
Dow Jones · 1d ago
Chromadex (CDXC) Receives a New Rating from a Top Analyst
In a report released today, Brian Nagel from Oppenheimer assigned a Buy rating to Chromadex (CDXC), with a price target of $17.00. The company's shares
SmarterAnalyst · 3d ago
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of -33.33% and -10.87%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 4d ago
8-K: ChromaDex Corp.
(EDGAR Online via COMTEX) -- ISDR Blueprint iXBRL Document 0001386570 false 0001386570 2060-05-06 2060-05-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CDXC. Analyze the recent business situations of ChromaDex through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CDXC stock price target is 15.00 with a high estimate of 18.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 109
Institutional Holdings: 16.57M
% Owned: 24.39%
Shares Outstanding: 67.93M
TypeInstitutionsShares
Increased
29
969.16K
New
15
253.49K
Decreased
21
284.66K
Sold Out
12
389.40K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.01%
Pharmaceuticals & Medical Research
-0.44%
Key Executives
Chairman/Executive Director
Frank Jaksch
Chief Executive Officer/Director
Robert Fried
Chief Financial Officer
Kevin Farr
Senior Vice President
Megan Jordan
Chief Marketing Officer
Fadi Karam
General Counsel/Secretary
Mark Friedman
Senior Director/IR Contact Officer
Brianna Gerber
Lead Director/Independent Director
Kurt Gustafson
Independent Director
Jeffrey Baxter
Independent Director
Stephen Block
Independent Director
Tony Lau
Independent Director
Steven Rubin
Independent Director
Wendy Yu
No Data
About CDXC
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.

Webull offers kinds of Chromadex Corp stock information, including NASDAQ:CDXC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDXC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CDXC stock methods without spending real money on the virtual paper trading platform.